Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.42 |
| ▸ | LIPE | Q05469 | 7/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14560 | 0.88 | LIPE (0.48) | AAK1LIPERXFP1LMNAPOLB | |
| SCHEMBL20312243 | 0.87 | LIPE (0.40) | LIPEALDH1A1 | |
| SCHEMBL30127865 | 0.87 | LIPE (0.40) | LIPEALDH1A1 | |
| SCHEMBL29984550 | 0.86 | AAK1 (0.41) | AAK1LIPERXFP1LMNAPOLB | |
| SCHEMBL16263673 | 0.86 | AAK1 (0.41) | AAK1LIPERXFP1LMNAPOLB | |
| SCHEMBL24497673 | 0.85 | AAK1 (0.41) | AAK1LIPERXFP1LMNAPOLB | |
| SCHEMBL28812261 | 0.84 | LIPE (0.44) | AAK1LIPERXFP1LMNAPOLB | |
| SCHEMBL13771762 | 0.84 | ALDH1A1 (0.42) | AAK1LIPELMNAALDH1A1 | |
| SCHEMBL34473719 | 0.84 | AAK1 (0.42) | AAK1LIPEP2RX7PRMT5WDR77 | |
| SCHEMBL20293692 | 0.83 | LIPE (0.39) | LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411398-B1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8785651-B2 | Method for manufacturing a boronic acid ester compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | GENENTECH, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | NISCH, BRSK1, BLK | AAK1 2316/4885LIPE 128/4885RXFP1 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.